Primer on Tumor Immunology and Cancer Immunotherapy™

A Pre-Conference Program; additional registration is required.

Wednesday, Nov. 9, 2022

8 a.m.–5 p.m. EST*

Omni Boston Hotel at the Seaport, Boston

Ensemble Ballroom

*Times and program schedule subject to change.

Program Organizers

  • Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

  • Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center

Target Audience

The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists and registered nurses.

Program Description 

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. The Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC attendees.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Review current approaches to immunotherapy including immune checkpoint modulation, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer and bispecific antibodies
  • Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Continuing Education

This program will be accredited to offer CME, CNE, CPE and MOC credits. 

SITC's Primer on Tumor Immunology and Cancer ImmunotherapyTM is supported in part by grants from Genentech, a member of the Roche Group, Incyte Corporation, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Pfizer, Inc. (as of October 24, 2022)

SITC Related Resources

SITC offers a variety of resources about immunology and immunotherapy. Explore the pages below to learn more.